Antimalarial medication multi-drug resistant "P. falciparum". It is a very potent blood schizonticide with a long half-life. It is thought to act by forming toxic heme complexes that damage parasitic food vacuoles. Mefloquine is effective in prophylaxis and for acute therapy. It is now used solely for the prevention of resistant strains of "P. falciparum" (usually combined with Artesunate) despite being effective against "P. vivax", "P. ovale" and "P. marlariae". Chloroquine/proguanil or sulfa drug-pyrimethamine combinations should be used in all other plasmodia infections. The major commercial manufacturer of mefloquine-based malaria treatment is Roche Pharmaceuticals, which markets the drug under the trade name
What Is the What "we really hadn’t decided whether I was just helping Valentino write his own book, or if I was writing a book about him." Valentino points out that, "I thought I might want to write my own book, but I learned that I was not ready to do this. I was still taking classes in basic writing at Georgia Perimeter College." Dave Eggers discusses the difficulties in writing a book of this nature: "For a long while there, we continued doing interviews, and I gathered the material. But all along, I really didn’t know exactly what form it would finally take—whether